A randomized mCRPC phase 2b study of the BET bromodomain inhibitor (BETi) zen-3694 and enzalutamide vesus enzalutamide.Rahul Raj Aggarwal,Michael Thomas Schweizer,David M. Nanus,Sarah Attwell,Eric Campeau,Emily Johnson,Philip Wegge,Lisa Bauman,Michael H. Silverman, Vandy Xu, Helena Zhu,Margo Snyder,Sanjay Lakhotia,Joshi J. AlumkalJOURNAL OF CLINICAL ONCOLOGY（2022）引用 1|浏览3暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
